A study of effects of pioglitazone and rosiglitazone on various parameters in patients of type-2 diabetes mellitus with special reference to lipid profile

Journal of Association of Physicians of India

Volumn 64, Issue September, 2016, Pages 24-28

  Sharma, S K ^a   Verma, S H ^b  

^a Department of Medicine ^*  (India)

^b MUZAFFARNAGAR MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ANALYSIS; BLOOD; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84985920513     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. King H, et al. Global burden of DM 1995-2025. Diabetes Care 1998; 21:1414-31.
2. Scheen AJ, Lefebvye PJ. Oral antidiabetic agents.A guide to selection. Drugs 1998; 55:225-36.
3. Bohannon NJ. Treating dual defects in diabetes: Insulin resistance and insulin secretion. Am J Heaith Syst Pharm 2002:1:59. Supple. 9:9-13.
4. Day C. TZD a new class of antidiabetic drugs. Diab Med 1999; 16:179-192.
5. Patrick J. Boyle. Allen Bennett King, Leann Olansky, et al. Effect of Pioglitazone and Rosiglitazone on Blood Lipid levels and Glycemic Control in Patients with Type -2 Diabetes Mellitus:- Clinical Therapeutics Vol.24, 3 (2002)
6. King AB, Armstrong D. Comparison of the glucose and lipid effects of rosiglitazone and pioglitazone following conversion from troglitazone treatment. Diabetes 50:A120, 2001
7. Khan MA, John V. ST. Peter, Pharmd, Jay L. Xue, Dvm, Phd 4 A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients With Type 2 Diabetes Who Were Previously Treated With Troglitazone Diabetes Care 2002; 25:708–711.
8. Gupta OP, et al. A study of prevalence of DM by means of house to house survey in Ahemedabad. Excerp. Med Inter Cong. Series. 211,6. 1970.
9. Dakshina Murthy 1984: Prevalence of DM
10. Ghosh SK, Sengupta B, Mookerjee GC, Bajaj, et al. Prospective study of glycemic status in India adults. In DM in developing countries Eds. 1984; 59-63.
11. Tripathy BB, Pande NC, Taj SC, et al. Survey for detection glycosuria,hyperglycemia and diabetes in urban and rural areas of Cuttack district. J Assoc Phy Ind 1974; 12,255.
12. Yoshinori Miyazaki, Masafumi Matsuda, Defonzo R. Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Diabetes Care March 2002; 25:517–523.
13. Aronoff S, Rosenblatt S, Braithwait S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 month randomized placebo-controlled doseresponse study. The Pioglitazone 001 Study Group.Diabetes Care November 2000; 23:1605-1611.
14. Sidney R, Barry M, Bradly GN, Prince Melvin J, Kenneth R. The Pioglitazone 026 Study Group. Coronary Artery Disease 2001; 12:413-423.
15. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RG, Demissie S, Fleck PR. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes and Vascular Disease Research 2006; 3:39-44.
16. Gegick CG, Altheimer MD: Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7:162–169.
17. Davidson PC, Sabbah HT, Steed RD, Richardson P, Robertson DG, Bode BW: Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone. Diabetes 2001; 50:A109.
18. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23:557.
19. Einhorn D, Kipnes M, Glazer NB, Wishner W. Durability of glycemic control with pioglitazone in long-term combination and monotherapy. Diabetes 2001; 50:A110.
20. King AB, Armstrong D: Characteristics of patients who gain weight while on pioglitazone treatment. Diabetes 2001; 50:A120.